An impending lead-manager change creates uncertainty for this otherwise strong healthcare strategy, prompting a downgrade of the People Pillar to Average from Above Average. Longtime lead manager Ziad Bakri announced in December 2025 that he will leave T. Rowe Price in July 2026 after a decade at the helm. His departure is certainly a loss, but incoming lead manager Jeff Holford knows the process well and plans to stick with it, supporting the decision to maintain an Above Average Process rating.
T. Rowe Price Health Sciences Fund PRHSX
- NAV / 1-Day Return 90.05 / +0.36 %
- Total Assets 11.9B
-
Adj. Expense Ratio
0.830%
- Expense Ratio 0.830%
- Distribution Fee Level Below Average
- Share Class Type No Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.11%
- Turnover 62%
USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 12:11 AM GMT+0
Morningstar’s Analysis PRHSX
Will PRHSX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 53.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 14.27 | 2B | Healthcare |
Aggregate Miscellaneous Equity | 7.63 | 912M | — |
Johnson & Johnson | 6.62 | 792M | Healthcare |
UnitedHealth Group Inc | 5.99 | 716M | Healthcare |
AbbVie Inc | 5.10 | 609M | Healthcare |
Merck & Co Inc | 4.00 | 479M | Healthcare |
Gilead Sciences Inc | 2.82 | 337M | Healthcare |
Thermo Fisher Scientific Inc | 2.52 | 301M | Healthcare |
Vertex Pharmaceuticals Inc | 2.28 | 272M | Healthcare |
Bristol-Myers Squibb Co | 2.11 | 252M | Healthcare |
United States